Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

d chest pain was longer in the afatinib arm(2)
  • The two most common side effects associated with treatment with afatinib were diarrhea (87% all grades, with 17% Grade 3) and rash/acne (79% all grades, with 14% Grade 3).  These side effects were usually well-managed by supportive care and dose reduction(2)

  • It is important to note that the overall study population, which included patients who received chemotherapy and one line of treatment with a first-generation EGFR inhibitor for at least 12 weeks, had a better performance status and lived longer than originally anticipated for patients with advanced NSCLC.  This information warrants further investigation of subpopulations in treatment of advanced NSCLC.

    LUX-Lung 2 Trial(3)

    Updated data from the phase II LUX-Lung 2 trial were also presented at the ESMO Congress.  The trial evaluated patients with advanced NSCLC who have EGFR mutations and were either untreated or progressed after one course of chemotherapy.  Analysis included the primary endpoint of objective response rate (ORR) as assessed by independent review.  Among 129 patients who received afatinib, the confirmed ORR by independent review was 57% and was similar to the confirmed ORR by investigator assessment (60%).  The secondary endpoints included OS (24 months), PFS (14 months) and disease control rate (86%).  The most common drug-related adverse events were diarrhea (95% all grades, with 19% Grade 3) and rash/acne (91% all grades, with 21% Grade 3).

    "Boehringer Ingelheim Oncology is dedicated to improving outcomes for patients with lung cancer and has multiple compounds in development to treat this disease," said Christopher Corsico, M.D., M.P.H., U.S. medical director, Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to further developing afatinib for the treatment of lung cancer and other tumors where continued unmet medical needs require additional treatm
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
    4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
    5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
    6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
    7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
    8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
    9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
    10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
    11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
    (Date:7/31/2015)... Ore., July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... testing services to healthcare insurers and physician groups, today ... 30, 2015. "In the second quarter ... year revenue growth of 54%, quarter over quarter revenue ... the installed base of FloChec® units of 18%," said ...
    (Date:7/31/2015)... -- According to a new market research ... (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air Displacement ... Forecast to 2019", published by MarketsandMarkets, the global Body ... and is estimated to grow to $1,425.7 Million by ... to 2019. Browse 41 market data ...
    Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
    ... May 26 CANTEL MEDICAL CORP. (NYSE: ... CEO, will be presenting at the Jefferies 2010 Global Life Sciences Conference. ... Wednesday, June 9, 2010 at The Grand Hyatt Hotel in ... following the presentation. In addition, Mr. Krakauer and Seth R. Segel ...
    ... DIEGO , May 26 In a recent study presented ... DC , researchers at the University of Texas MD Anderson ... neoadjuvant chemotherapy. , , , ... are high-resolution breast PET systems that can show the location as well ...
    Cached Medicine Technology:Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference 2Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy 2
    (Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... on in Chicago at Grant Park. The festival will end on Sunday, August ... to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts ...
    (Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near ... Ride to Fight On is a cycling fundraiser that benefits the West Cancer Center, ... The University of Tennessee Health Science Center. A health and wellness festival featuring food, ...
    (Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to the article published ... of the Pasadena courthouse was contained and extinguished by the city’s fire department before it ... the building at the time of the fire, and it was a fire alarm system ...
    (Date:7/31/2015)... ... 31, 2015 , ... Cosmetic Town has proven itself as ... plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. ... and fillers. , Staying up to date with the latest cosmetic trends ...
    Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
    ... new study has indicated the steps by which an breastfeeding women ... have shown that the overweight women who are breastfeeding and want ... amount of sweetened drinks, snack foods, sweets and desserts in their ... for 45 minutes per day, for at least four days in ...
    ... Vermont say that drinking cherry juice may be the antidote ... and anti-inflammatory compounds that can deal with a number of ... of Sports Medicine, researchers said that men and women who ... markers in their blood. The study examined 14 male college ...
    ... after menopause could increase the risk of breast cancer, says a ... studied over 87,000 women, aged 30 to 55 years for up ... noted how it had changed since, reported the online edition of ... through menopause during the course of the study were also assessed ...
    ... Organization has communicated to countries the benefits of building up ... companies have sent in their request// to Roche AG, the ... combat a potential bird-flu pandemic. ,Though U.S ... yet they have enabled companies a list of things to ...
    ... have their say on whether patients should have to opt ... medical profession is concerned that, in the proposed summary care ... the patient, and this is not being made sufficiently clear ... in a letter to this week's journal. ,"Patients ...
    ... the debate with many others to discuss on the focus ... women.// Instead of giving a conceptual argument on the similarities ... and proved. ,Barres' experience as a female-to-male transgendered ... July 13 issue of Nature rebuking the comments of former ...
    Cached Medicine News:Health News:Diet & Exercise regime Not Harmful For Overweight, Lactating Mothers Or their Infants 2Health News:Electronic Patient Record "Serious Threat" to Patient Confidentiality 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 3Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 4
    ENDO STITCH™ Single Use Loading Units....
    ... single use suturing device has application ... of interrupted or running stitches in ... use suturing device is available in ... with the choice of 4 suture ...
    ... Suture Assistant is a sterile, single-patient-use instrument ... and in placing a suture and a ... button to tie a secure intracorporeal knot., ... the ENDOPATH 5mm trocars or larger trocars ...
    ... 42" long suture inserted into a plastic tube. ... and scored on the other. The suture protrudes ... ST-3 needle. The opposite end of the suture ... plastic tube. The scored end acts as the ...
    Medicine Products: